Development of the Thalassaemia Adult Life Index (ThALI).
Beta Thalassaemia Major
development
quality of life
Journal
Health and quality of life outcomes
ISSN: 1477-7525
Titre abrégé: Health Qual Life Outcomes
Pays: England
ID NLM: 101153626
Informations de publication
Date de publication:
12 Jun 2020
12 Jun 2020
Historique:
received:
06
11
2019
accepted:
05
06
2020
entrez:
14
6
2020
pubmed:
14
6
2020
medline:
12
9
2020
Statut:
epublish
Résumé
Beta Thalassaemia Major (βTM) is a chronic genetic illness whereby the challenges faced by patients exposes them to increased risk of psychosocial issues. Despite this, a disease-specific tool to measure the impact of this illness on adult patients has yet to be developed. In collaboration with βTM adult patients, this study aimed to develop a comprehensive, disease-specific, easy to use psychometrically sound tool to measure the impact of chelation and transfusion dependent βTM in a cross-cultural patient group in England.The Thalassaemia Life Index (ThALI) was developed in two stages - item generation and pre-testing and item reduction - in collaboration with service users. Recruited adult patients shaped the design of the instrument including its statements and subscales. Standard item reduction techniques were used to develop the instrument. The final version of the ThALI encompasses 35 statements and five sub-scales - general physical health, coping, body image, appearance and confidence, social relationships and autonomy. This endorses the multidimensionality of quality of life (QoL). The factor structure of the ThALI is highly stable and its internal consistency is high (alpha = 0.87 for the overall scale; 0.83-0.94 for its subscales). The ThALI has sound scaling assumptions, acceptability and score variability. Content validity was confirmed by experts and service user interviewees. The loadings for the items retained were adequate and the item discriminant validity sound. The ThALI covers the impact of βTM in adult patients. Preliminary testing shows its multidimensionality to be reliable and valid. The national authentication of the tool with patients treated in Centres of Excellence will aim to provide further evidence regarding the ThALI's psychometric properties. Once authenticated, the ThALI may be utilised in research and in clinical settings to assess the effects of new therapies and/or interventions from the patients' perspective to inform practice and/or to identify areas of concern.
Sections du résumé
BACKGROUND
BACKGROUND
Beta Thalassaemia Major (βTM) is a chronic genetic illness whereby the challenges faced by patients exposes them to increased risk of psychosocial issues. Despite this, a disease-specific tool to measure the impact of this illness on adult patients has yet to be developed.
METHODS
METHODS
In collaboration with βTM adult patients, this study aimed to develop a comprehensive, disease-specific, easy to use psychometrically sound tool to measure the impact of chelation and transfusion dependent βTM in a cross-cultural patient group in England.The Thalassaemia Life Index (ThALI) was developed in two stages - item generation and pre-testing and item reduction - in collaboration with service users. Recruited adult patients shaped the design of the instrument including its statements and subscales. Standard item reduction techniques were used to develop the instrument.
RESULTS
RESULTS
The final version of the ThALI encompasses 35 statements and five sub-scales - general physical health, coping, body image, appearance and confidence, social relationships and autonomy. This endorses the multidimensionality of quality of life (QoL). The factor structure of the ThALI is highly stable and its internal consistency is high (alpha = 0.87 for the overall scale; 0.83-0.94 for its subscales). The ThALI has sound scaling assumptions, acceptability and score variability. Content validity was confirmed by experts and service user interviewees. The loadings for the items retained were adequate and the item discriminant validity sound.
CONCLUSIONS
CONCLUSIONS
The ThALI covers the impact of βTM in adult patients. Preliminary testing shows its multidimensionality to be reliable and valid. The national authentication of the tool with patients treated in Centres of Excellence will aim to provide further evidence regarding the ThALI's psychometric properties. Once authenticated, the ThALI may be utilised in research and in clinical settings to assess the effects of new therapies and/or interventions from the patients' perspective to inform practice and/or to identify areas of concern.
Identifiants
pubmed: 32532297
doi: 10.1186/s12955-020-01437-6
pii: 10.1186/s12955-020-01437-6
pmc: PMC7291498
doi:
Types de publication
Journal Article
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
180Références
BMC Blood Disord. 2002 Nov 20;2(1):4
pubmed: 12441006
Qual Life Res. 1995 Jun;4(3):241-8
pubmed: 7613534
Ann N Y Acad Sci. 1998 Jun 30;850:349-54
pubmed: 9668557
Health Psychol. 1999 Sep;18(5):495-505
pubmed: 10519466
Semin Hematol. 1996 Jan;33(1):53-65
pubmed: 8714585
Lancet. 2000 Jun 10;355(9220):2051-2
pubmed: 10885361
Bull World Health Organ. 2001;79(11):1006-13
pubmed: 11731807
West J Med. 2000 Feb;172(2):124-8
pubmed: 10693376
Med Care. 1992 Jun;30(6):473-83
pubmed: 1593914
Lancet. 2016 Oct 8;388(10053):1459-1544
pubmed: 27733281
Ann N Y Acad Sci. 1998 Jun 30;850:355-60
pubmed: 9668558
Br J Haematol. 2014 Feb;164(3):431-7
pubmed: 24180641
Qual Life Res. 2015 Jan;24(1):147-51
pubmed: 25008261
Psychol Med. 1979 Feb;9(1):139-45
pubmed: 424481
Ann N Y Acad Sci. 1998 Jun 30;850:361-9
pubmed: 9668559
Adv Ther. 2010 Aug;27(8):533-46
pubmed: 20652657
Med Care. 1989 Mar;27(3 Suppl):S217-32
pubmed: 2646490
Mayo Clin Proc. 2002 Apr;77(4):371-83
pubmed: 11936935
Patient Prefer Adherence. 2012;6:477-97
pubmed: 22848151
Health Expect. 2017 Oct;20(5):871-877
pubmed: 28703473